Catexel
Catexel, officially known as Catexel GmbH, is a leading player in the biotechnology industry, headquartered in Germany. Founded in 2015, the company has rapidly established itself as a key innovator in the development of advanced biopharmaceuticals and therapeutic solutions, primarily focusing on regenerative medicine and cellular therapies. With a strong operational presence across Europe and North America, Catexel is renowned for its unique approach to harnessing the potential of stem cells and biomaterials. Their core products, which include cutting-edge cell-based therapies and tissue engineering solutions, are distinguished by their efficacy and safety profiles. Catexel's commitment to research and development has positioned it as a market leader, achieving significant milestones in clinical trials and collaborations with prominent research institutions. This dedication to innovation continues to drive the company’s growth and influence within the biotechnology sector.
DitchCarbon Score
How does Catexel's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Catexel's score of 10 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Catexel's reported carbon emissions
In 2023, Catexel reported total carbon emissions of approximately 161,990,000 kg CO2e. This figure includes 15,247,000 kg CO2e from Scope 1 emissions, 22,436,000 kg CO2e from Scope 2 emissions, and a significant 124,307,000 kg CO2e from Scope 3 emissions. Comparatively, in 2022, the company had total emissions of about 144,001,000 kg CO2e, with Scope 1 emissions at 8,542,000 kg CO2e, Scope 2 at 24,439,000 kg CO2e, and Scope 3 at 111,020,000 kg CO2e. The emissions data for 2021 mirrored that of 2022, indicating a consistent emission level over these years. Despite the increase in total emissions from 2022 to 2023, Catexel has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of formal climate pledges or SBTi (Science Based Targets initiative) commitments suggests that while the company is aware of its emissions, it has yet to establish a structured approach to reducing them. Catexel's emissions profile highlights the importance of addressing Scope 3 emissions, which constitute the majority of their carbon footprint. As the company continues to operate in a climate-conscious industry, developing a comprehensive strategy for emissions reduction will be crucial for aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 8,542,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 24,439,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 111,020,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Catexel is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
